Celltrion is a global biopharmaceutical company fully integrated from research and development to commercialization. With a strong commitment to improving patient outcomes, Celltrion develops and delivers innovative biologics and biosimilars to patients in more than 100 countries worldwide. In the gastroenterology field, Celltrion offers multiple Health Canada–approved biologics, including Remdantry (infliximab IV), Remsima SC (infliximab SC), Yuflyma (adalimumab), and Steqeyma (ustekinumab), with a rich pipeline that continues to expand treatment options for Canadian patients. Through Celltrion Connect, our comprehensive patient support program, we provide personalized services, including nutrition, physiotherapy, and mental health support, to help patients receive optimal care throughout their treatment journey.

To learn more about our mission and pipeline, please visit: www.celltrionhealthcare.ca
For more information about Celltrion’s Patient Support Program, please visit: www.celltrionconnect.ca